Showing results (561-570 of 1,826) with videos related to

Sort By:
Pageof 183
Signal Transduction and Targeted Therapy|December 14, 2025
Abrogation of aberrant glycolytic interactions eliminates senescent cells and alleviates aging-related dysfunctionsTakumi Mikawa, Masahiro Kameda, Sumiko Ikari, et al.
Signal Transduction and Targeted Therapy|December 20, 2025
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinomaRan Xue, Miaoyan Wei, Jiajia Yuan, et al.
Signal Transduction and Targeted Therapy|April 27, 2025
Nuclear mitochondrial acetyl-CoA acetyltransferase 1 orchestrates natural killer cell-dependent antitumor immunity in colorectal cancerChen Wei, Kun Liao, Hao-Jie Chen, et al.
Signal Transduction and Targeted Therapy|April 27, 2025
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycanLi Li, Jiajia Wu, Weiqian Cao, et al.
Signal Transduction and Targeted Therapy|April 3, 2025
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advancesChen Xue, Qingfei Chu, Qingmiao Shi, et al.
Signal Transduction and Targeted Therapy|April 17, 2025
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancerZhengyu Zha, Chunxiao Liu, Meisi Yan, et al.
Signal Transduction and Targeted Therapy|May 9, 2025
Myeloid but not hepatocytic CD38 is a key driver for hepatic ischemia/reperfusion injuryQi-Hang Zhao, Ya-Ting Zhang, Ke Wen, et al.
Signal Transduction and Targeted Therapy|May 4, 2025
Meningeal lymphatic drainage: novel insights into central nervous system diseaseQiang Zhang, Yin Niu, Yingpei Li, et al.
Signal Transduction and Targeted Therapy|April 24, 2025
Bio-barrier-adaptable biomimetic nanomedicines combined with ultrasound for enhanced cancer therapyJuan Guo, Xueting Pan, Qingyuan Wu, et al.
Signal Transduction and Targeted Therapy|May 6, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Yi Ba, Junye Wang, et al.
Pageof 183